Another study demonstrated that SRC-1 modulates endocrine-resistant breast cancer progression through an epigenetic reprogramming pathway, and a set of prodifferentiation genes associated with poor clinical outcome (i.e., NR2F2, NTRK2, SETBP1, CTDP1, and POU3F2) were found to be hypermethylated by SRC-1 combined with a complex of methylators [64]. This evidence concerns the gene NCOA1 and breast cancer.